Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6/STAT3 and TLR4 Signaling Pathways.
B7-H1 Antigen
/ genetics
Cell Line, Tumor
Colonic Neoplasms
/ genetics
Extracellular Vesicles
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Inflammation
/ genetics
Interleukin-6
/ genetics
STAT3 Transcription Factor
/ genetics
Signal Transduction
/ genetics
Toll-Like Receptor 4
/ genetics
Tumor-Associated Macrophages
/ immunology
M0 macrophages
PD-L1
TLR4
colorectal cancer
multiple myeloma
small extracellular vesicles
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Nov 2021
09 Nov 2021
Historique:
received:
06
10
2021
revised:
27
10
2021
accepted:
03
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
16
12
2021
Statut:
epublish
Résumé
Tumor-associated macrophages play a key role in promoting tumor progression by exerting an immunosuppressive phenotype associated with the expression of programmed cell death ligand 1 (PD-L1). It is well known that tumor-derived small extracellular vesicles (SEVs) affect the tumor microenvironment, influencing TAM behavior. The present study aimed to examine the effect of SEVs derived from colon cancer and multiple myeloma cells on macrophage functions. Non-polarized macrophages (M0) differentiated from THP-1 cells were co-cultured with SEVs derived from a colorectal cancer (CRC) cell line, SW480, and a multiple myeloma (MM) cell line, MM1.S. The expression of PD-L1, interleukin-6 (IL-6), and other inflammatory cytokines as well as of the underlying molecular mechanisms were evaluated. Our results indicate that SEVs can significantly upregulate the expressions of PD-L1 and IL-6 at both the mRNA and protein levels and can activate the STAT3 signaling pathway. Furthermore, we identified the TLR4/NF-kB pathway as a convergent mechanism for SEV-mediated PD-L1 expression. Overall, these preliminary data suggest that SEVs contribute to the formation of an immunosuppressive microenvironment.
Identifiants
pubmed: 34829995
pii: ijms222212118
doi: 10.3390/ijms222212118
pmc: PMC8621495
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Interleukin-6
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione AIRC per la Ricerca sul Cancro to Riccardo Alessandro
ID : n°18783
Références
Exp Cell Res. 2020 Nov 15;396(2):112315
pubmed: 33031808
J Leukoc Biol. 2010 Nov;88(5):877-84
pubmed: 20573802
Int J Mol Sci. 2020 Mar 26;21(7):
pubmed: 32225076
J Clin Invest. 2018 Apr 2;128(4):1708
pubmed: 29608143
Med Sci Monit. 2018 Aug 08;24:5501-5508
pubmed: 30087314
J Cell Physiol. 2019 Aug;234(10):16824-16837
pubmed: 30784085
J Clin Invest. 2018 Feb 1;128(2):580-588
pubmed: 29337303
Cancer Immunol Res. 2015 Dec;3(12):1303-7
pubmed: 26307625
Cancers (Basel). 2020 Feb 14;12(2):
pubmed: 32075123
Int J Mol Sci. 2020 May 31;21(11):
pubmed: 32486375
Blood. 2007 Jul 1;110(1):296-304
pubmed: 17363736
Oncotarget. 2015 Aug 14;6(23):19514-27
pubmed: 26098775
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33749663
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Neuro Oncol. 2010 Nov;12(11):1113-25
pubmed: 20667896
Oncoimmunology. 2017 Aug 18;6(12):e1362527
pubmed: 29209566
J Immunol. 2019 May 15;202(10):3065-3075
pubmed: 30979816
Oncoimmunology. 2018 Jan 16;7(4):e1412909
pubmed: 29632728
J Extracell Vesicles. 2020 Jan 7;9(1):1710899
pubmed: 32002173
Cancer Res. 2019 Sep 15;79(18):4715-4728
pubmed: 31337655
Sci Immunol. 2017 Jul 28;2(13):
pubmed: 28754746
Pharmacol Ther. 2014 Feb;141(2):125-39
pubmed: 24076269
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581055
Front Pharmacol. 2019 Apr 24;10:389
pubmed: 31068809
Front Immunol. 2020 Nov 25;11:584626
pubmed: 33324403
Biomed Res Int. 2018 Apr 16;2018:8459193
pubmed: 29850577
Exp Mol Med. 2019 Aug 9;51(8):1-13
pubmed: 31399559
Ann Oncol. 2015 Apr;26(4):812-817
pubmed: 25600565
J Immunol. 2014 Sep 1;193(5):2218-29
pubmed: 25070848
J Exp Clin Cancer Res. 2019 Sep 11;38(1):397
pubmed: 31506076
Ann Oncol. 2020 May;31(5):599-608
pubmed: 32178965
Glia. 2011 Feb;59(2):242-55
pubmed: 21125645
Mol Med Rep. 2014 Oct;10(4):2172-6
pubmed: 25051048
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Foods. 2020 Sep 14;9(9):
pubmed: 32937843
J Cell Physiol. 2019 Feb;234(2):1313-1325
pubmed: 30191996
J Immunol. 2007 Nov 1;179(9):6318-24
pubmed: 17947709
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Immunity. 2007 Jul;27(1):111-22
pubmed: 17629517
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
Clin Cancer Res. 2019 Jun 15;25(12):3643-3657
pubmed: 30824583
Mol Immunol. 2017 Aug;88:58-68
pubmed: 28600970
Sci Rep. 2017 Jul 5;7(1):4711
pubmed: 28680152
Sci Rep. 2017 May 11;7(1):1755
pubmed: 28496107
Oncotarget. 2016 Jul 26;7(30):47252-47264
pubmed: 27322149
Pathol Res Pract. 2020 Apr;216(4):152881
pubmed: 32089413
Mol Oncol. 2018 Mar;12(3):269-286
pubmed: 28865178
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
J Immunol. 2000 Jun 15;164(12):6166-73
pubmed: 10843666
Liver Cancer. 2019 Mar;8(2):110-120
pubmed: 31019901
Cancer Sci. 2021 Mar;112(3):997-1010
pubmed: 33247999
Int J Mol Sci. 2019 Oct 28;20(21):
pubmed: 31661771
Hum Vaccin Immunother. 2019;15(5):1111-1122
pubmed: 30888929
Cell Death Dis. 2018 Mar 19;9(4):422
pubmed: 29556041
Br J Cancer. 2013 Aug 6;109(3):529
pubmed: 23921279
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
PLoS One. 2019 Sep 27;14(9):e0222614
pubmed: 31560702